Sunshine Biopharma (SBFM) Intangibles (2015 - 2026)

Sunshine Biopharma has reported Intangibles for 7 years, with the latest figure at $1.9 million in Q1 2026.

• For the quarter ending Q1 2026, Intangibles fell 39.94% year-over-year to $1.9 million; the trailing twelve-month figure through Mar 2026 stood at $1.9 million (down 39.94% YoY), and the FY2025 full-year result was $1.9 million, down 37.43% from the prior year.
• Intangibles for Q1 2026 stood at $1.9 million, up from $1.9 million in the prior quarter.
• The five-year high for Intangibles was $3.2 million in Q1 2025, with the low at $776856.0 in Q4 2022.
• Historically, Intangibles has averaged $2.0 million across 5 years, with a median of $2.0 million in 2024.
• Annual changes were most pronounced in 2024 — Intangibles soared 149.84% — and 2026, when it sank 39.94%.
• Sunshine Biopharma's Intangibles stood at $776856.0 in 2022, then soared by 85.91% to $1.4 million in 2023, then surged by 109.08% to $3.0 million in 2024, then plunged by 37.43% to $1.9 million in 2025, then gained by 1.51% to $1.9 million in 2026.
• The last three Intangibles figures came in at $1.9 million (Q1 2026), $1.9 million (Q4 2025), and $2.1 million (Q3 2025), per Business Quant data.